Top High Dividend Stocks To Watch Right Now

Tobacco companies have always offered high dividends, and have been associated with strong balance sheets. Lorillard (LO), despite hailing from an unhealthy industry, is poised to continue raising its safely maintained dividends. The company will find plenty of tobacco huffers in the developing world, if it can build out its international presence. Below is some insight into the company.

Lorillard�� flagship brands include Newport, Kent, True, Maverick, Old Gold, Blu electronic cigarettes (e- cigs) and the recently acquired British e-cig brand SKYCIG. Lorillard's flagship cigarette Newport is by far the most popular brand of mentholated cigarettes. Lorillard produces cigarettes for both the premium and discount segments of the domestic cigarette market. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year and expanding profit margins.

Good Numbers

Lorillard's performance has been boosted by strength across the tobacco sector. Yield-starved investors look to tobacco stocks for their hefty dividend yields to generate income for their portfolios.

Hot Services Stocks To Invest In 2015: Whiting Petroleum Corporation(WLL)

Whiting Petroleum Corporation engages in the acquisition, development, exploitation, exploration, and production of oil and gas primarily in the Permian Basin, Rocky Mountains, Mid-Continent, Gulf Coast, and Michigan regions of the United States. As of December 31, 2010, its estimated proved reserves were 304.9 million barrels equivalent of oil; and had interests in 9,698 gross productive wells covering approximately 1,115,000 gross developed acres. The company sells its oil and gas to end users, marketers, and other purchasers. Whiting Petroleum Corporation was founded in 1983 and is Denver, Colorado.

Advisors' Opinion:

• [By Caiman Valores]

  But its reserves are lower than U.S. domiciled small-cap Stone Energy (SGY) and mid-cap Whiting Petroleum (WLL). However, in the case of Stone Energy a larger portion of its proved and probable reserves are lower margin and less profitable natural gas, with natural gas making up 51% of its reserves and oil and NGLs the remaining 49%.

• [By Joel South and Taylor Muckerman]

  In the following video, Motley Fool energy analysts Joel South and Taylor Muckerman look at the bigger picture of what's happening with oil production in the Bakken today, and why Bakken oil sells for dramatically less of a discount to West Texas Intermediate than it did last year. Joel then tells us about Whiting Petroleum (NYSE: WLL  ) , and what the tailwinds are for this company that make it is his favorite player in the Bakken today.

• [By Ben Levisohn]

  Since Friday, three major acquisitions have been announced. AECOM Technology�(ACM) said it would buy URS�(URS) for $4 billion; Mylan�(MYL) agreed to pay $5.3 billion for�Abbott Laboratories�(ABT) non-U.S. generic drug business; and Whiting Petroleum (WLL) said it would take over Kodiak Oil & Gas (KOG). And amazingly, none of them appear to be overpriced.

Top High Dividend Stocks To Watch Right Now: Groupe Eurotunnel SA (GET)

Groupe Eurotunnel SA, (also GET SA), is a France-based company having its expertise in infrastructure management and railway operations. It manages and operates the Channel Tunnel between the United Kingdom and France and its railway infrastructure. The Company is also engaged in passenger and freight transport between continental Europe and the United Kingdom. In addition, it provides ferry transport through the Channel. Groupe Eurotunnel SA has direct and indirect stakes in a number of companies, including The Channel Tunnel Group Limited, France Manche SA, Europorte SAS, Europorte Channel SAS, Europorte Proximite SAS, GB Railfreight Limited, Eurotunelplus GmbH and others. Advisors' Opinion:

• [By Robert Wall]

  At the same time it faces new competition as Deutsche Bahn plans services from Germany to London via the Channel Tunnel from 2016 after a three-year safety study, Groupe Eurotunnel SA (GET), which runs the 30-mile subsea link, said in June.

Top High Dividend Stocks To Watch Right Now: Lantrovision(s)

Lantrovision (S) Ltd engages in the design, installation, supply, and provision of consultancy services on network integration and structured cabling. It is involved in the design and installation of computer cabling, as well as the trade of related accessories and peripherals; provision of cabling infrastructure services; sale of cabling accessories; and provision of system integration and network infrastructure services, as well as offers installation, maintenance, and support services for structured cabling systems and components. The company also engages in the structure, design, installation, and consultation of network system with computer communication technology. In addition, it manufactures and sells structuralized cable laying system and multimedia technology; trades in computer peripherals, electronic components, and products for various applications, planners, consultants, advisors, and managers in relation to computer services; and supplies data backup and ret rieval systems. Further, the company provides solutions for testing, monitoring, and analyzing enterprise and telecommunication networks; and contracting services for voice, data, and telecommunication. It primarily operates in Singapore, Malaysia, Hong Kong, China, and Korea, as well as in Thailand and the Philippines. The company was founded in 1990 and is based in Singapore.

Advisors' Opinion:

• [By Evan Niu, CFA]

  Speaking of the iPhone, T-Mobile has sold roughly 500,000 so far in a little less than a month. Not a bad start considering that translates into a quarterly run rate of about 1.5 million, which is how many iPhones than larger rival Sprint Nextel (NYSE: S  ) sold during the first quarter.

• [By Dan Caplinger]

  Until recently, it looked as though the two Dow telecoms would be able to create an effective duopoly in the U.S. market, leaving other companies to fight for the scraps that they left behind. But Sprint Nextel's (NYSE: S  ) renaissance from the support of Japan's SoftBank has thwarted that outcome, making the No. 3 carrier a legitimate player once more and giving AT&T and Verizon a run for their money. Nevertheless, Sprint has a lot of work to do before it can hope to catch up to its larger rivals.

• [By Evan Niu, CFA]

  Apple (NASDAQ: AAPL  ) just posted its earnings figures last night, almost at the exact same time that domestic main flame AT&T (NYSE: T  ) put up its own digits. Last week, Verizon (NYSE: VZ  ) shared its iPhone figures, and this morning Sprint Nextel (NYSE: S  ) told investors how many iPhones it activated during the quarter.

• [By WALLSTCHEATSHEET]

  Sprint Nextel provides mobile communications solutions to a growing audience in the United States and its territories. The stock is in a long-term downtrend but seems to be setting up for higher prices in the near-term, a possible indication of a long-term trend shift. Earnings are still shrinking, for the company, while revenues have been steadily increasing which has not impressed investors. Relative to its peers and sector, Sprint Nextel has been a year-to-date performance leader. Look for Sprint Nextel stock to continue to OUTPERFORM.

Top High Dividend Stocks To Watch Right Now: Hyperion Therapeutics Inc (HPTX)

Hyperion Therapeutics, Inc. (Hyperion), incorporated in November 2006, is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company develops Ravicti (glycerol phenylbutyrate) to treat the prevalent urea cycle disorders (UCD) and hepatic encephalopathy (HE). The Company has completed two Phase II trials and one pivotal Phase III trial of Ravicti. The Company�� HE clinical program consists of two trials, which have enrolled patients with cirrhosis. On December 23, 2011, the Company submitted a new drug application (NDA) for Ravicti for the chronic management of UCD in patients aged six years and above based on data from its pivotal Phase III trial in adult patients and the results of two Phase II trials, one in adults and one in pediatric patients aged 6 through 17 years. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.

In June 2011, the Company completed a 24-month carcinogenicity study of Ravicti in rats. On March 22, 2012, pursuant to an asset purchase agreement (purchase agreement) with Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation, the Company purchased all of the worldwide rights to Ravicti. The Company also has an option to acquire all of Ucyclyd�� worldwide rights in BUPHENYL and AMMONUL (sodium phenylacetate and sodium benzoate) injection.

The Company conducted a pivotal Phase III trial of Ravicti in adult patients 18 years of age or older with UCD. The Company completed a second Phase II trial at five centers in North America in UCD patients aged 6 through 17 years. This trial includes two phases: a two-week, open-label, safety, tolerability, pharmacokinetic characteristics and ammonia control of Ravicti. The Co! mpany enrolled 77 adult and pediatric UCD patients in its two 12-month open-label safety studies, 69 of whom completed the studies. The Company conducted nonclinical genotoxicity and carcinogenicity studies to assess the tumorigenic potential of Ravicti in animals and to assess the relevant risk in humans. The Company is conducting a Phase II multi-center study of patients with cirrhosis and episodic HE.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Hyperion Therapeutics (NASDAQ: HPTX  ) , a biopharmaceutical company focused on treatments for orphan diseases and hepatology, rose as much as 10% after receiving orphan drug exclusivity status for Ravicti from the Food and Drug Administration, and exercising an option to acquire two additional urea cycle drugs from Valeant Pharmaceuticals (NYSE: VRX  ) .

• [By Jesse Solomon]

  NPS Pharmaceuticals (NPSP), for example, created a drug for treating short bowel syndrome. And Hyperion Therapeutics (HPTX) is developing a drug for hepatic encephalopathy, a decline of brain function that according to the National Institute of Health occurs when the liver is no longer able to remove toxins from the blood. Those stocks are up 20% and 40%, respectively, this year.